Tamoxifen is one of the important SERMs for ER positive breast cancers [36] and it competitively inhibits the recruitment of transcription coactivators by ER, hence shutting down the transcription of ER responsive genes [37]. This evidence concerns the gene ESR1 and breast cancer.